Table 4b.

Comparison of the diagnostic performance of prediction models and clinical indicators in the validation group (csPCa).

Indicators	AUC	95% CI	Cutoff	Sensitivity	Specificity	PPV	NPV	p
t-PSA	0.610	0.501–0.718	13.480	0.383	0.92	64.29%	77.86%	0.047
PSAD	0.733	0.643–0.823	0.290	0.660	0.732	50.00%	83.51%	<0.000
PIRADS score	0.847	0.785–0.910	3	0.851	0.777	40.00%	97.73%	<0.000
T2WI score	0.815	0.747.0.883	3	0.767	0.901	38.87%	94.76	<0.000
DWI score	0.830	0.763–0.897	3	0.766	0.777	36.72%	100.00%	<0.000
Total score	0.888	0.838–0.938	5	0.914	0.714	43.93%	100.00%	<0.000
Model 1	0.872	0.817–0.926	0.944	0.872	0.741	57.75%	93.18%	<0.000
Model 2	0.910	0.865–0.954	1.101	0.915	0.732	58.90%	95.35%	<0.000

tPSA, total PSA; PSAD, PSA density; PI-RADS score, prostate imaging reporting and date system score; T2WI score, T2WI score referring to PI-RADS v2; DWI score, DWI score referring to PI-RADS score; csPCa, clinical significant prostate cancer; Total score, T2WI score + DWI score. Model 1 = f/tPSA + PSAD + T2WI score. Model 2 = f/tPSA + PSAD + Total score; AUC, area under the curve; 95% CI, 95% confidence interval for AUC; Cutoff, best cutoff; PPV, positive predictive value; NPV, negative predictive value.